Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 20:11:733.
doi: 10.3389/fphar.2020.00733. eCollection 2020.

Discovering Anti-Cancer Drugs via Computational Methods

Affiliations
Review

Discovering Anti-Cancer Drugs via Computational Methods

Wenqiang Cui et al. Front Pharmacol. .

Abstract

New drug discovery has been acknowledged as a complicated, expensive, time-consuming, and challenging project. It has been estimated that around 12 years and 2.7 billion USD, on average, are demanded for a new drug discovery via traditional drug development pipeline. How to reduce the research cost and speed up the development process of new drug discovery has become a challenging, urgent question for the pharmaceutical industry. Computer-aided drug discovery (CADD) has emerged as a powerful, and promising technology for faster, cheaper, and more effective drug design. Recently, the rapid growth of computational tools for drug discovery, including anticancer therapies, has exhibited a significant and outstanding impact on anticancer drug design, and has also provided fruitful insights into the area of cancer therapy. In this work, we discussed the different subareas of the computer-aided drug discovery process with a focus on anticancer drugs.

Keywords: AI; CADD; anti-cancer; computational methods; drug discovery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A workflow for drug discovery: from target identification to drug approval.
Scheme 1
Scheme 1
Successful applications of computational methods in anti-cancer drug discovery.

References

    1. Al-Salama Z. T., Keam S. J. (2019). Entrectinib: first global approval. Drugs 79, 1477–1483. 10.1007/s40265-019-01177-y - DOI - PubMed
    1. Al-Salama Z. T. (2019). Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. Drugs 79, 1591–1598. 10.1007/s40265-019-01194-x - DOI - PubMed
    1. Anthony C. S., Masuyer G., Sturrock E. D., Acharya K. R. (2012). Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors. Curr. Med. Chem. 19, 845–855. 10.2174/092986712799034950 - DOI - PubMed
    1. Atkins M. B., Plimack E. R., Puzanov I., Fishman M. N., Mcdermott D. F., Cho D. C., et al. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19, 405–415. 10.1016/S1470-2045(18)30081-0 - DOI - PMC - PubMed
    1. Blair H. A. (2018). Duvelisib: First global approval. Drugs 78, 1847–1853. 10.1007/s40265-018-1013-4 - DOI - PubMed

LinkOut - more resources